An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. / Offersgaard, Anna; Duarte Hernandez, Carlos Rene; Feng, Shan; Marichal-Gallardo, Pavel; Holmbeck, Kenn; Pihl, Anne Finne; Fernandez-Antunez, Carlota; Alzua, Garazi Peña; Hartmann, Katrine Top; Pham, Long V.; Zhou, Yuyong; Gammeltoft, Karen Anbro; Fahnøe, Ulrik; Schneider, Uffe Vest; Pedersen, Gabriel Kristian; Jensen, Henrik Elvang; Christensen, Jan Pravsgaard; Ramirez, Santseharay; Bukh, Jens; Gottwein, Judith Margarete.

I: iScience, Bind 26, Nr. 2, 105949, 2023.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Offersgaard, A, Duarte Hernandez, CR, Feng, S, Marichal-Gallardo, P, Holmbeck, K, Pihl, AF, Fernandez-Antunez, C, Alzua, GP, Hartmann, KT, Pham, LV, Zhou, Y, Gammeltoft, KA, Fahnøe, U, Schneider, UV, Pedersen, GK, Jensen, HE, Christensen, JP, Ramirez, S, Bukh, J & Gottwein, JM 2023, 'An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals', iScience, bind 26, nr. 2, 105949. https://doi.org/10.1016/j.isci.2023.105949

APA

Offersgaard, A., Duarte Hernandez, C. R., Feng, S., Marichal-Gallardo, P., Holmbeck, K., Pihl, A. F., Fernandez-Antunez, C., Alzua, G. P., Hartmann, K. T., Pham, L. V., Zhou, Y., Gammeltoft, K. A., Fahnøe, U., Schneider, U. V., Pedersen, G. K., Jensen, H. E., Christensen, J. P., Ramirez, S., Bukh, J., & Gottwein, J. M. (2023). An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience, 26(2), [105949]. https://doi.org/10.1016/j.isci.2023.105949

Vancouver

Offersgaard A, Duarte Hernandez CR, Feng S, Marichal-Gallardo P, Holmbeck K, Pihl AF o.a. An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience. 2023;26(2). 105949. https://doi.org/10.1016/j.isci.2023.105949

Author

Offersgaard, Anna ; Duarte Hernandez, Carlos Rene ; Feng, Shan ; Marichal-Gallardo, Pavel ; Holmbeck, Kenn ; Pihl, Anne Finne ; Fernandez-Antunez, Carlota ; Alzua, Garazi Peña ; Hartmann, Katrine Top ; Pham, Long V. ; Zhou, Yuyong ; Gammeltoft, Karen Anbro ; Fahnøe, Ulrik ; Schneider, Uffe Vest ; Pedersen, Gabriel Kristian ; Jensen, Henrik Elvang ; Christensen, Jan Pravsgaard ; Ramirez, Santseharay ; Bukh, Jens ; Gottwein, Judith Margarete. / An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. I: iScience. 2023 ; Bind 26, Nr. 2.

Bibtex

@article{2b3d65b5031a42b89b6131e2a383275a,

title = "An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals",

abstract = "Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralizing antibodies in mice; moreover, lyophilized antigen was immunogenic. Following homologous challenge, I-SARS-CoV-2 immunized hamsters were protected against disease and lung pathology. In contrast with reports for widely used vaccines, hamster plasma similarly neutralized the homologous and the Delta (B.1.617.2) variant viruses, whereas the Omicron (B.1.1.529) variant was neutralized less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.",

keywords = "Immune response, Immunology, Virology",

author = "Anna Offersgaard and {Duarte Hernandez}, {Carlos Rene} and Shan Feng and Pavel Marichal-Gallardo and Kenn Holmbeck and Pihl, {Anne Finne} and Carlota Fernandez-Antunez and Alzua, {Garazi Pe{\~n}a} and Hartmann, {Katrine Top} and Pham, {Long V.} and Yuyong Zhou and Gammeltoft, {Karen Anbro} and Ulrik Fahn{\o}e and Schneider, {Uffe Vest} and Pedersen, {Gabriel Kristian} and Jensen, {Henrik Elvang} and Christensen, {Jan Pravsgaard} and Santseharay Ramirez and Jens Bukh and Gottwein, {Judith Margarete}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

doi = "10.1016/j.isci.2023.105949",

language = "English",

volume = "26",

journal = "iScience",

issn = "2589-0042",

publisher = "Elsevier",

number = "2",

}

RIS

TY - JOUR

T1 - An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals

AU - Offersgaard, Anna

AU - Duarte Hernandez, Carlos Rene

AU - Feng, Shan

AU - Marichal-Gallardo, Pavel

AU - Holmbeck, Kenn

AU - Pihl, Anne Finne

AU - Fernandez-Antunez, Carlota

AU - Alzua, Garazi Peña

AU - Hartmann, Katrine Top

AU - Pham, Long V.

AU - Zhou, Yuyong

AU - Gammeltoft, Karen Anbro

AU - Fahnøe, Ulrik

AU - Schneider, Uffe Vest

AU - Pedersen, Gabriel Kristian

AU - Jensen, Henrik Elvang

AU - Christensen, Jan Pravsgaard

AU - Ramirez, Santseharay

AU - Bukh, Jens

AU - Gottwein, Judith Margarete

PY - 2023

Y1 - 2023

N2 - Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralizing antibodies in mice; moreover, lyophilized antigen was immunogenic. Following homologous challenge, I-SARS-CoV-2 immunized hamsters were protected against disease and lung pathology. In contrast with reports for widely used vaccines, hamster plasma similarly neutralized the homologous and the Delta (B.1.617.2) variant viruses, whereas the Omicron (B.1.1.529) variant was neutralized less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.

AB - Vaccines have relieved the public health burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and globally inactivated vaccines are most widely used. However, poor vaccination accessibility and waning immunity maintain the pandemic, driving emergence of variants. We developed an inactivated SARS-CoV-2 (I-SARS-CoV-2) vaccine based on a viral isolate with the Spike mutation D614G, produced in Vero cells in a scalable bioreactor, inactivated with β-propiolactone, purified by membrane-based steric exclusion chromatography, and adjuvanted with MF59-like adjuvant AddaVax. I-SARS-CoV-2 and a derived split vaccine induced persisting neutralizing antibodies in mice; moreover, lyophilized antigen was immunogenic. Following homologous challenge, I-SARS-CoV-2 immunized hamsters were protected against disease and lung pathology. In contrast with reports for widely used vaccines, hamster plasma similarly neutralized the homologous and the Delta (B.1.617.2) variant viruses, whereas the Omicron (B.1.1.529) variant was neutralized less efficiently. Applied bioprocessing approaches offer advantages regarding scalability and production, potentially benefitting worldwide vaccine coverage.

KW - Immune response

KW - Immunology

KW - Virology

U2 - 10.1016/j.isci.2023.105949

DO - 10.1016/j.isci.2023.105949

M3 - Journal article

C2 - 36644321

AN - SCOPUS:85147575087

VL - 26

JO - iScience

JF - iScience

SN - 2589-0042

IS - 2

M1 - 105949

ER -

ID: 337600843